Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market

Pfizer and Roche Also In The Running

Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.

Great excitement surrounded Merck & Co interim results last week, which showed that its investigational antiviral pill molnupiravir had cut the risk of hospitalization or death by half in a Phase III trial in people with mild or moderate COVID-19, and now analysts are sizing up just how big an impact it could make.

However, arriving at a consensus is difficult given the unpredictable dynamics of the pandemic, vaccination programs and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

09 May 2025

• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.